DWTX, US92829J2033

H.C. Wainwright reiterates Buy for Dogwood Therapeutics stock

Published on 10/06/2026 at 08:37 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Dogwood enrolled 239 patients on September 14, 2026. For Dogwood Therapeutics stock, November data follow a USD 11.5 million second-quarter loss.

DWTX, US92829J2033, Illustration mit AI erstellt.

Dogwood Therapeutics (ISIN US92829J2033) received a reiterated Buy rating and a USD 12.00 price target from H.C. Wainwright on October 2, 2026, according to The Globe and Mail. The analyst call arrives as the biotechnology company prepares for a clinical readout that could define the next stage of its pipeline.

November data set the next test

Dogwood completed enrollment of 239 patients in its randomized Halneuron Phase 2b trial for chemotherapy-induced neuropathic pain on September 14, 2026. Dogwood Therapeutics said topline data are expected in November 2026.

The trial compares Halneuron with placebo and follows participants for 28 days. Its primary endpoint measures the change in weekly average daily pain intensity from baseline to week four, making the November result more significant for valuation than the enrollment milestone itself.

Losses keep financing central

Dogwood reported adjusted earnings per share of minus USD 0.34 for the second quarter of 2026, versus consensus of minus USD 0.14, a USD 0.20 shortfall, according to MarketBeat. The comparison shows why clinical execution and access to capital remain closely linked for this development-stage company.

Dogwood posted a net loss of USD 11.5 million in the second quarter of 2026, while cash stood at USD 9.6 million at June 30, 2026, according to Quartr. The cash position places the November readout alongside a funding question, because clinical progress must be matched by sufficient resources to continue development.

Nasdaq snapshot before the readout

Dogwood Therapeutics was last at USD 1.52 on Nasdaq on October 5, 2026 at 4:00 p.m. EDT, up 4.11 percent from USD 1.46. Its market capitalization was USD 51.1 million, and the 52-week range was USD 1.28 to USD 7.20 as of the same date. Dogwood develops Halneuron and SP16 IV for pain and neuropathy indications.